Bariks Health

**Product and the concrete problem it solves.** Bariks Health attacks one of the most stubborn access problems in modern medicine: hyperbaric oxygen therapy (HBOT) works, but the machines that deliver it are effectively immovable. Clinical-grade hard chambers are large, heavy, plumbed-in steel pressure vessels that live in hospitals and specialized clinics, and a standard course of treatment demands that a patient physically travel to that fixed installation daily for six-to-eight weeks. That logistics burden gates the therapy off from most of the people and situations that could benefit — home users, athletes, longevity clinics, rural areas, and, critically, emergency and field settings where a casualty cannot be moved to a hospital chamber in time. Bariks's answer is a **patented, foldable, lightweight portable HBOT chamber** that reportedly weighs about 25 kilograms, folds into a suitcase-class form factor that fits in a car trunk (the company and press describe it packing into two suitcases), and can be deployed on-site. The pitch inverts the model: instead of moving the patient to the chamber, you move the chamber to the patient — into homes, athletic facilities, wellness centers, and emergency scenarios including explosions, diving accidents, and carbon-monoxide poisoning.

**Core technology and how it actually works.** Hyperbaric oxygen therapy places the body in a pressurized environment breathing elevated oxygen so that oxygen dissolves directly into blood plasma at concentrations unreachable at ambient pressure, driving tissue repair, angiogenesis, and cellular recovery. Bariks's engineering claim is that it delivers this at up to **3 ATA (atmospheres absolute)** in a portable package — a meaningful specification, because low-cost "soft" portable chambers on the market typically top out near ~1.3 ATA, well below the ~2–3 ATA pressures used for serious clinical indications, while 3-ATA capability has historically required rigid, fixed installations. Achieving 3 ATA in a foldable ~25 kg body is the company's core differentiator, and Bariks states it holds **patents on both the chamber-body material and its software platform**, developed with an Israeli specialist manufacturing partner over roughly four years. On top of the hardware sits an AI-driven software layer for personalized session protocols, digital monitoring, and data analysis, positioning the chamber as a connected device rather than a passive pressure vessel. One important calibration: Bariks's own consumer website markets the device as a **wellness product and explicitly disclaims that it is a cleared medical device** (stating it is not FDA/EMA approved and not intended to diagnose, treat, cure, or prevent disease), even as trade coverage describes medical and defense casualty applications — the medical/defense pathway is emerging, not a fielded, regulator-cleared claim.

**Market, customers, and go-to-market.** Bariks addresses a broad, fast-growing set of adjacent markets rather than a single vertical: elite and professional sport recovery, longevity and anti-aging, cognitive enhancement, aesthetics, clinical and at-home care, and defense/emergency response. Its go-to-market combines **direct sales and a rental model**, which lowers the adoption barrier for high-ticket hardware and can convert a one-time device sale into recurring revenue and services (session software, monitoring, maintenance). The portability thesis is the wedge: the same device that a longevity clinic or a sports team buys for recovery is the device that can be forward-deployed to a first-responder unit or a military medical detachment. Public reporting indicates the company projects sales in the hundreds of millions of shekels within several years — an ambition that should be read as a target, not traction — and that it planned a commercial launch in early 2024 after its multi-year development period.

**Traction, funding, and third-party validation.** Bariks is early-stage but carries unusually strong validation signals for its size. It received a **grant from the Israel Innovation Authority of roughly $3 million (structured as about $1 million per year over three years, beginning in the first half of 2023)** — a non-dilutive government endorsement of the technical program. It subsequently raised a **~$7 million round led by Nir Zuk, the founder of Palo Alto Networks**, who made a personal investment and **joined the board of directors**; **Nir Zohar, president of Wix**, is also cited as a shareholder. Zuk's involvement is the strongest external diligence signal in the public record: a marquee cybersecurity founder personally backing an Israeli medical-hardware company and taking a board seat is meaningful third-party validation of the team and the opportunity, even though it does not confirm revenue, unit economics, or regulatory clearance. The most concrete real-world usage claim in the public record is that Bariks has provided chambers **to the IDF for treating blast injuries, smoke inhalation, and diving accidents** — an operational reference that, if durable, distinguishes it from purely consumer HBOT vendors.

**Founders and team background.** The founding bench is the standout asset. Bariks was established in 2018 and is led by **Boaz Misholi** (co-chairman), a serial Israeli technology entrepreneur associated with founding **Comverse** and **Fundtech** among other companies; **Admiral (res.) Yedidya Ya'ari** (co-chairman), the **former commander of the Israeli Navy and former CEO of Rafael Advanced Defense Systems** — precisely the profile that opens defense-medical channels and lends credibility on ruggedized, mission-critical hardware; **Dr. Yehuda Melamed** (medical director), a pioneer of diving and hyperbaric medicine in Israel and the domain authority behind the clinical rationale; and **Amir Shukrun** (CEO), who brings a private-equity/management background. This is a rare combination of proven company-building, senior defense leadership, and deep hyperbaric-medicine expertise. Notably, the company's development center is at **Kibbutz Nirim near the Gaza border**, and the team was directly affected by the October 7, 2023 attack — its software manager, Nadav Poppelwell, was kidnapped and killed — a human dimension that also underscores operational and geographic exposure.

**Competitive dynamics.** Bariks sits between two competitor sets. (1) Against **traditional clinical HBOT incumbents** — fixed hard-chamber manufacturers such as Sechrist, Perry Baromedical, and HBOT integrators like Israel's own Aviv Clinics/Aviv Scientific ecosystem — it trades the very top of clinical pressure/volume for radical portability and lower installation cost. (2) Against **consumer/soft portable chamber vendors** (numerous low-pressure ~1.3 ATA "mild HBOT" brands) it differentiates on the 3-ATA pressure claim, patented materials, and clinical/defense positioning. (3) It also implicitly competes with the **status-quo alternative of no treatment** in field and home settings, where a fixed chamber simply is not an option. Bariks's plausible edges are: (i) a genuinely higher portable pressure ceiling than typical soft chambers; (ii) patented chamber-body material and software IP; (iii) a defense- and medicine-credentialed founding team with IDF access; and (iv) a rental-plus-sale model that lowers adoption friction. The countervailing reality is that HBOT's clinical evidence base beyond a handful of approved indications remains contested, and the wellness/longevity framing invites regulatory and efficacy scrutiny.

**Defense, security, and resilience dual-use relevance.** Bariks's dual-use case is credible and rests on casualty care and resilience rather than on any weapons capability. A portable, higher-pressure oxygen chamber maps directly onto battlefield and mass-casualty medicine: **blast and pressure-wave (barotrauma) injuries, traumatic brain injury, smoke inhalation, burns, crush injuries, and diving/submarine accidents** are exactly the conditions where hyperbaric oxygen is indicated and where the ability to bring 3-ATA capability forward — to a field hospital, a naval vessel, or a forward aid station — could matter operationally. The IDF-usage reference and a co-founder who formerly led both the Israeli Navy and Rafael make the defense channel concrete rather than aspirational. Honest calibration: the device is marketed commercially as a wellness product without regulatory clearance, so its defense value today is an **emerging casualty-care and resilience adjacency** validated by early IDF use, not a certified, broadly fielded military medical system. Its strategic weight will scale with clinical validation, regulatory posture, and formal defense-medical procurement.

**Growth stage, trajectory, and key diligence risks.** Bariks reads as an **early-stage** company: founded 2018, a multi-year development cycle, an early-2024 commercial launch, roughly $10 million in combined grant and equity capital, and a small team. The trajectory — from IIA-grant-funded R&D to a marquee-investor equity round and an initial IDF reference — is a healthy early arc, but the risks are material. (1) **Regulatory ambiguity:** the consumer site disclaims medical-device status while press describes medical/defense use; the path to FDA/CE clearance for clinical or defense-medical claims is undefined in the public record and could be long and costly. (2) **Efficacy and evidence:** HBOT's clinical benefit outside established indications is scientifically contested, exposing the wellness/longevity positioning to scrutiny. (3) **Scale and capital:** ~$10 million is thin for medical-hardware manufacturing, regulatory work, and go-to-market, implying further raises. (4) **Operational/geographic exposure:** a development center at Kibbutz Nirim on the Gaza border, and a team directly harmed on October 7, 2023, carry real continuity risk. (5) **Commercial concentration and disclosure:** revenue, unit economics, headcount, order backlog, and the depth of the IDF relationship are not publicly confirmable. Progression would be evidenced by regulatory clearances, published clinical data, disclosed defense-medical procurement, and transparent commercial traction.